english.prescrire.org > Spotlight > 100 most recent > Why drugs should be evaluated in several randomised comparative trials

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Why drugs should be evaluated in several randomised comparative trials

 Editorial  Every year, the Prescrire Drug Awards are based on the reviews published in the Marketing Authorisations section of Prescrire's French edition over the past year. For the 2024 Prescrire Drug Awards, as in previous years, we chose not to give awards to certain drugs that were evaluated in a single comparative trial, even when the trial showed the drug to represent a therapeutic advance for patients. Examples include: darolutamide, for use in combination with docetaxel in certain metastatic prostate cancers; and dostarlimab, for use in combination with first-line chemotherapy in certain endometrial cancers. What is the reason for this choice?
Full article available for download (FREE)

It is a fundamental principle of experimental science that the reproducibility of the result of a scientific experiment should be verified, to make sure that the result was not due to chance alone or a flaw in the experiment's design. This principle also applies to the evaluation of a drug's efficacy. There can be rare exceptions, for example when the drug's efficacy is so clear that one trial is sufficient to show that it radically transforms the prognosis of the disease in question. This is the case for the recipient of the Pilule d'Or (Golden Pill) in the 2024 Prescrire Drug Awards, fexinidazole in sleeping sickness due to infection with Trypanosoma brucei rhodesiense ("The Prescrire Awards for 2024" Prescrire Int May 2025, FREE).

In a comparative trial, even if the difference observed between two groups is statistically significant according to the protocol, it is still possible that the results obtained were due to chance alone, that recruitment bias was not recognised, that an error occurred during data collection, that the data were manipulated, etc. The uncertainty surrounding the results of a single comparative clinical trial is greatly reduced when similar results, obtained in another trial, conducted independently by a different team, are available.

Yet, in 2024, drug regulatory agencies very often endorsed marketing authorisations based only on a single comparative trial, and have been doing so for many years. This is highly regrettable, because it can result in the use of drugs whose harm-benefit balance is uncertain.

 ©Prescrire 1 May 2025

Source: "Why drugs should be evaluated in several randomised comparative trials" Prescrire Int 2025; 34 (270): 115. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:

"The Prescrire Awards for 2024"
Prescrire Int 2025;
34 (270): 136-139.
FREE

"Darolutamide (Nubeqa°)
in combination with docetaxel
in metastatic hormone-sensitive
prostate cancer"
Prescrire Int 2024;
33 (260): 150.
Subscribers only

"Dostarlimab (Jemperli°)
in advanced or recurrent
endometrial cancer with
DNA repair defects"
Prescrire Int 2025;
34 (267): 40-41.
Subscribers only

"Fexinidazole
(Fexinidazole Winthrop°)
in sleeping sickness
caused by Trypanosoma
brucei rhodesiense"
Prescrire Int 2025;
34 (269): 94-95.
Subscribers only